Consequence and management of atrial fibrillation in chronic lymphocytic lymphoma patients treated with ibrutinib or ibrutinib plus rituximab: An international retrospective study

Trial Profile

Consequence and management of atrial fibrillation in chronic lymphocytic lymphoma patients treated with ibrutinib or ibrutinib plus rituximab: An international retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Results (n=56) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 19 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top